^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CD19-CAR.CD45RA- negative T-cells

    i
    Other names: CD19-CAR.CD45RA- negative T-cells, CD19-directed allogeneic memory T-cell therapy, CD19-CAR(Mem) T-cells, CD19-CAR.CD45RA-negative T-cells
    Associations

    News

    Trials
    Company:
    St. Jude Children's Research Hospital
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    9ms
    Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia (clinicaltrials.gov)
    P1, N=60, Recruiting, St. Jude Children's Research Hospital | Trial completion date: Jan 2026 --> Jun 2027 | Trial primary completion date: Jan 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • CD19-CAR.CD45RA- negative T-cells
    over3years
    Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia (clinicaltrials.gov)
    P1, N=60, Recruiting, St. Jude Children's Research Hospital
    Clinical • New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    fludarabine IV • mesna • CD19-CAR.CD45RA- negative T-cells • cyclophosphamide intravenous